Corrigendum to "Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: Meta-analyses of published studies" [Contemp. Clin. Trials 53 (2017) 20-28]
Contemp Clin Trials
.
2017 Sep:60:126.
doi: 10.1016/j.cct.2017.06.015.
Epub 2017 Jul 14.
Authors
Madan G Kundu
1
,
Suddhasatta Acharyya
2
Affiliations
1
Novartis Pharmaceutical Corporation, East Hanover, NJ, USA. Electronic address: madan_g.kundu@novartis.com.
2
Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
PMID:
28716496
DOI:
10.1016/j.cct.2017.06.015
No abstract available
Publication types
Published Erratum